Hyloris Pharmaceuticals SA (HYL.BR)

13.62 €

+0.18 (+1.34%)
Rating:
Recommendation:
-
Symbol HYL.BR
Price 13.62 €
Beta 0.568
Volume Avg. 0.00M
Market Cap 381.365M
Shares () -
52 Week Range 12.2-19.1
1y Target Est -
DCF Unlevered HYL.BR DCF ->
DCF Levered HYL.BR LDCF ->
ROE -7.88% Neutral
ROA -5.92% Neutral
Operating Margin -
Debt / Equity 20.44% Neutral
P/E -30.27 Strong Sell
P/B 5.29 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Stijn Van Rompay
Healthcare
Biotechnology
Brussels

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.